N6022是选择性且可逆的S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，IC50为8nM，Ki为2.5nM。
Cas No.:1208315-24-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
N6022 is a selective and reversible inhibitor of S-nitrosoglutathione reductase (GSNOR), with an IC₅₀ of 8nM and a Kᵢ of 2.5nM[1-2]. N6022 exhibits multiple biological functions by binding to the GSNO substrate-binding pocket, thereby increasing intracellular levels of S-nitrosoglutathione (GSNO) and modulating protein S-nitrosylation signaling pathways[3-4].
In vitro, in an oxygen-glucose deprivation/reperfusion (OGD/R) model using BV2 microglial cells, treatment with N6022 (1–10μM) at the onset of reperfusion for 22 hours significantly enhanced cell viability, attenuated the decline in mitochondrial membrane potential, reduced the expression of the pro-apoptotic protein BAX, and upregulated the expression of Bcl-2[5]. In murine myoblast C2C12 cells treated with N6022 (200μM) for 72 hours, N6022 markedly increased mitochondrial numbers and induced the accumulation of endoplasmic reticulum vesicles[6].
In vivo, in a C57BL/6J mouse model of acetaminophen (APAP)-induced acute liver injury, intraperitoneal administration of N6022 (5mg/kg) at 2 hours post-APAP injection significantly reduced serum levels of liver injury markers AST and ALT, alleviated hepatic necrosis and apoptosis, and suppressed the expression of inflammatory factors[7]. In a spinal cord injury (SCI) model in C57BL/6J mice, N6022 (5mg/kg) was administered via tail vein injection starting at 2 hours post-injury and continued for 4 weeks. N6022 significantly improved motor function (as assessed by BMS scores), reduced pain-like behaviors, and ameliorated depressive-like behaviors[8].
References:
[1] Sun X, Qiu J, Strong SA, et al. Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3671-5.
[2] Colagiovanni DB, Drolet DW, Langlois-Forget E, et al. A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma. Regul Toxicol Pharmacol. 2012 Feb;62(1):115-24.
[3] Blonder JP, Mutka SC, Sun X, et al. Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation. BMC Pulm Med. 2014 Jan 10;14:3.
[4] Khan M, Kumar P, Qiao F, et al. Targeting GSNOR for functional recovery in a middle-aged mouse model of stroke. Brain Res. 2020 Aug 15;1741:146879.
[5] Duan WL, Ma YP, Wang XJ, et al. N6022 attenuates cerebral ischemia/reperfusion injury-induced microglia ferroptosis by promoting Nrf2 nuclear translocation and inhibiting the GSNOR/GSTP1 axis. Eur J Pharmacol. 2024 Jun 5;972:176553.
[6] Li J, Wu W, Ji G, et al. L-NAME improves the morphology and necrosis of skeletal muscle by activating PINK1-PARKIN mediated mitophagy in mdx mice. Brain Dev. 2025 Aug;47(4):104388.
[7] Cui Q, Jiang T, Xie X, et al. S-nitrosylation attenuates pregnane X receptor hyperactivity and acetaminophen-induced liver injury. JCI Insight. 2024 Jan 23;9(2):e172632.
[8] Khan M, Qiao F, Islam SMT, et al. GSNOR and ALDH2 alleviate traumatic spinal cord injury. Brain Res. 2021 May 1;1758:147335. doi: 10.1016/j.brainres.2021.147335.
N6022是选择性且可逆的S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，IC50为8nM，Ki为2.5nM[1-2]。N6022具有多种生物学功能，N6022通过结合GSNO底物结合口袋，从而增加细胞内S-亚硝基谷胱甘肽（GSNO）的水平，进而调节蛋白质S-亚硝基化信号通路发挥作用[3-4]。
在体外，在氧糖剥夺/再灌注（OGD/R）BV2小胶质细胞模型中，N6022（1–10μM）于再灌注时处理细胞并培养22小时，N6022能显著提高细胞活力，减轻线粒体膜电位下降，并减少细胞凋亡相关蛋白BAX的表达，同时上调Bcl-2的表达[5]。N6022（200μM）处理小鼠成肌细胞C2C12细胞72小时，N6022显著增加细胞内线粒体数量并诱导内质网囊泡积聚[6]。
在体内，在乙酰氨基酚（APAP）诱导的急性肝损伤C57BL/6J小鼠2小时后，N6022（5mg/kg）腹腔注射给药，显著降低了肝损伤标志物AST和ALT的血清水平，减轻了肝组织坏死和细胞凋亡，并抑制了炎症因子的表达[7]。N6022（5mg/kg）通过尾静脉注射，在C57BL/6J小鼠脊髓损伤（SCI）后2小时开始给药，持续治疗4周。N6022显著改善脊髓损伤后的运动功能（BMS评分）、减轻疼痛样行为和抑郁样行为[8]。
| Cell experiment [1]: | |
Cell lines | C2C12 cells (murine myoblast cell line) |
Preparation Method | C2C12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. C2C12 cells were treated with N6022 at a concentration of 200µM for 72 hours. |
Reaction Conditions | 200µM; 72h |
Applications | N6022 significantly increased the number of mitochondria and induced the accumulation of endoplasmic reticulum vesicles in C2C12 cells. N6022 also upregulated the expression of the mitophagy-related protein PINK1. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice (wild-type and GSNOR⁻/⁻) |
Preparation Method | Mice were subjected to spinal cord contusion injury at the T9-T10 vertebral level. N6022 (5mg/kg) was administered intravenously via tail vein injection at 2 hours post-injury, followed by daily injections until the study endpoint (up to 4 weeks). |
Dosage form | 5mg/kg; i.v.; Daily injections for 4 weeks. |
Applications | N6022 treatment significantly improved locomotor function, reduced pain-like behaviors, and alleviated depressive-like symptoms in SCI mice. N6022 also attenuated blood-spinal cord barrier disruption, edema, and neuroinflammation by inhibiting GSNOR activity, thereby promoting functional recovery. |
References: | |
| Cas No. | 1208315-24-5 | SDF | |
| 化学名 | 3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid | ||
| Canonical SMILES | CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O | ||
| 分子式 | C24H22N4O3 | 分子量 | 414.46 |
| 溶解度 | ≥ 20.7mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4128 mL | 12.0639 mL | 24.1278 mL |
| 5 mM | 482.6 μL | 2.4128 mL | 4.8256 mL |
| 10 mM | 241.3 μL | 1.2064 mL | 2.4128 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet